MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia; and SKNY-1, that is in preclinical stage for obesity and nicotine dependence. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida. Show more
1200 Brickell Avenue, Miami, FL, 33131, United States
Market Cap
32.8M
52 Wk Range
$0.60 - $2.45
Previous Close
$0.78
Open
$0.79
Volume
138,507
Day Range
$0.76 - $0.83
Enterprise Value
24.49M
Cash
8.113M
Avg Qtr Burn
-1.206M
Insider Ownership
30.58%
Institutional Own.
5.42%
Qtr Updated
06/30/26
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Ketamir-2 Details Neuropathic pain | Phase 2a Initiation | |
MIRA-55 (Non-Opioid Analgesic) Details Inflammatory Pain | IND Submission | |
SKNY-1 (Small Molecule) Details Weight Loss And Nicotine Addiction | IND Submission |
